A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer

This is a Phase Ib, open label, dose escalation study of spartalizumab + LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in adult patients with advanced or metastatic TNBC.
During the dose-escalation part of each treatment arm, patients will be treated with fixed doses of spartalizumab + LAG525 in combination with partner investigational drugs to be escalated until the MTD is reached or a lower RDE is established: NIR178, capmatinib, MCS110, or canakinumab. It is anticipated that other partner study drugs may be added in the future by protocol amendment.
After the determination of the MTD/RDE for a particular treatment arm, dose expansion may begin in that arm in order to further assess safety, tolerability, PK/PD, and anti-tumor activity of each combination at the MTD/RDE. Dose expansion arms may initiate only after consideration by the Investigators and Novartis of all available toxicity information, the assessment of risk to future patients from the BLRM, and the available PK, preliminary efficacy, and PD information. There is no requirement for dose-escalation treatment arms reaching an MTD/RDE to proceed to dose expansion.

Start Date31 Jan 2019

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT03484923 / CompletedPhase 2

A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma

The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

Start Date10 Sep 2018

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT03499899 / CompletedPhase 2

A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer

The main purpose of this study was to assess the antitumor activity of three combinations: i) LAG525 + spartalizumab; ii) LAG525 + spartalizumab + carboplatin, and iii) LAG525 + carboplatin in participants with advanced triple-negative breast cancer (TNBC) in first or second line therapy.

Start Date02 Jul 2018

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

100 Clinical Results associated with Ieramilimab

100 Translational Medicine associated with Ieramilimab

100 Patents (Medical) associated with Ieramilimab

Literatures (Medical) associated with Ieramilimab

31 Dec 2024·OncoImmunology

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

Article

Author: Askoxylakis, Vasileios ; Sarantopoulos, John ; Lin, Chia-Chi ; Hui, Rina ; Martin, Miguel ; Akerley, Wallace ; Carvajal, Richard D ; Esaki, Taito ; Kwak, Eunice L ; Gusenleitner, Daniel ; Ma, Brigette ; Weickhardt, Andrew ; Rispoli, Lawrence ; Tan, Daniel Sw ; Soo, Ross A ; Garralda, Elena ; Kyi, Chrisann ; Cassier, Philippe A ; Zhang, Tian ; Samant, Tanay S ; Deschler-Baier, Barbara ; Maur, Michela ; Chowdhury, Niladri Roy ; Schöffski, Patrick ; Chiu, Joanne ; Hong, David S ; Spratlin, Jennifer ; Rolland, Fréderic ; De Braud, Filippo ; Siu, Lillian L

Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination treatment in patients with selected advanced (locally advanced or metastatic) solid malignancies. Eligible patients with non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), mesothelioma, and triple-negative breast cancer (TNBC) were grouped depending on prior anti-PD-1/L1 therapy (anti-PD-1/L1 naive or anti-PD-1/L1 pretreated). Patients received ieramilimab (400 mg) followed by spartalizumab (300 mg) every 3 weeks. The primary endpoint was objective response rate (ORR), along with safety, pharmacokinetics, and biomarker assessments. Of 235 patients, 142 were naive to anti-PD-1/L1 and 93 were pretreated with anti-PD-1/L1 antibodies. Durable responses (>24 months) were seen across all indications for patients naive to anti-PD-1/L1 and in melanoma and RCC patients pretreated with anti-PD1/L1. The most frequent study drug-related AEs were pruritus (15.5%), fatigue (10.6%), and rash (10.6%) in patients naive to anti-PD-1/L1 and fatigue (18.3%), rash (14.0%), and nausea (10.8%) in anti-PD-1/L1 pretreated patients. Biomarker assessment indicated higher expression of T-cell-inflamed gene signature at baseline among responding patients. Response to treatment was durable (>24 months) in some patients across all enrolled indications, and safety findings were in accordance with previous and current studies exploring LAG-3/PD-1 blockade.

01 Jan 2023·Frontiers in oncology

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report.

Author: Caputo, Roberta ; Pensabene, Matilde ; Parola, Sara ; Pagliuca, Martina ; De Laurentiis, Michelino

While standard treatment has shown efficacy in patients with breast cancer gene (BRCA) mutations, recurrence rates are high and additional effective therapies are needed. Olaparib, a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, approved for the treatment of metastatic germline BRCA1/BRCA2 breast cancer (BC), has demonstrated evidence of a progression-free survival (PFS) benefit, good safety profile, and improved quality of life compared with standard chemotherapy. We here describe the case of a patient with BRCA1 mutated advanced BC and a long history of response to chemotherapy and immunotherapy who received systemic treatment with olaparib. First diagnosed in March 2011 at the age of 38 years with early-stage BC of the right breast, she underwent quadrantectomy plus ipsilateral axillary lymphadenectomy and adjuvant treatments with chemotherapy regimen containing 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by radiotherapy. Five years later, following a contralateral nodule detection leading to left breast quadrantectomy, she received adjuvant systemic treatment with docetaxel plus cyclophosphamide and radiotherapy. Gene testing showed a germline BRCA1 deleterious variant, and she underwent bilateral prophylactic mastectomy and oophorectomy. One year later, skin metastasis and bone infiltrations were detected, and she was started on first-line systemic treatment. The patient was enrolled in the IMpassion131 trial (investigating atezolizumab addition to paclitaxel) but unblinding showed that she was randomized in the placebo arm. She received second-line systemic therapy with LAG525 plus carboplatin (CLAG525B2101 trial) resulting in a PFS of 14 months. At disease progression, she was eligible for systemic third-line therapy with olaparib (300 mg twice daily) and had a complete response after 6 months of therapy and a PFS of 40 months at the time of writing. To the best of our knowledge, this is the first report of a complete response following treatment with third-line systemic olaparib in a long-responding patient and relatively good tolerability and quality of life, pre-treated with both chemotherapy and immunotherapy.

01 Feb 2022·Journal for ImmunoTherapy of CancerQ2 · MEDICINE

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Q2 · MEDICINE

ArticleOA

Author: Samant, Tanay S ; Kyi, Chrisann ; Hui, Rina ; Askoxylakis, Vasileios ; Krauss, Jürgen ; De Braud, Filippo ; Ramesh, Radha ; Soo, Ross A ; Carion, Ana ; Hu, Tiancen ; Schöffski, Patrick ; Patel, Nidhi ; Chowdhury, Niladri Roy ; Hong, David S ; Weickhardt, Andrew ; Gusenleitner, Daniel ; Ochoa-de-Olza, María ; Martín, Miguel ; Longmire, Tyler ; Prawira, Amy ; Yerramilli-Rao, Padmaja ; Esaki, Taito ; Deschler-Baier, Barbara ; Tan, Daniel S W ; Lau, Allen ; Akerley, Wallace ; Carvajal, Richard D ; Kwak, Eunice L ; Sarantopoulos, John ; Zhang, Tian ; Maur, Michela ; Sabatos-Peyton, Catherine A

BackgroundLymphocyte-activation gene 3 (LAG-3) is an inhibitory immunoreceptor that negatively regulates T-cell activation. This paper presents preclinical characterization of the LAG-3 inhibitor, ieramilimab (LAG525), and phase I data for the treatment of patients with advanced/metastatic solid tumors with ieramilimab ±the anti-programmed cell death-1 antibody, spartalizumab.MethodsEligible patients had advanced/metastatic solid tumors and progressed after, or were unsuitable for, standard-of-care therapy, including checkpoint inhibitors in some cases. Patients received ieramilimab ±spartalizumab across various dose-escalation schedules. The primary objective was to assess the maximum tolerated dose (MTD) or recommended phase II dose (RP2D).ResultsIn total, 255 patients were allocated to single-agent ieramilimab (n=134) and combination (n=121) treatment arms. The majority (98%) had received prior antineoplastic therapy (median, 3). Four patients experienced dose-limiting toxicities in each treatment arm across various dosing cohorts. No MTD was reached. The RP2D on a 3-week schedule was declared as 400 mg ieramilimab plus 300 mg spartalizumab and, on a 4-week schedule (once every 4 weeks; Q4W), as 800 mg ieramilimab plus 400 mg spartalizumab; tumor target (LAG-3) suppression with 600 mg ieramilimab Q4W was predicted to be similar to the Q4W, RP2D schedule. Treatment-related adverse events (TRAEs) occurred in 75 (56%) and 84 (69%) patients in the single-agent and combination arms, respectively. Most common TRAEs were fatigue, gastrointestinal, and skin disorders, and were of mild severity; seven patients experienced at least one treatment-related serious adverse event in the single-agent (5%) and combination group (5.8%). Antitumor activity was observed in the combination arm, with 3 (2%) complete responses and 10 (8%) partial responses in a mixed population of tumor types. In the combination arm, eight patients (6.6%) experienced stable disease for 6 months or longer versus six patients (4.5%) in the single-agent arm. Responding patients trended towards having higher levels of immune gene expression, includingCD8andLAG3, in tumor tissue at baseline.ConclusionsIeramilimab was well tolerated as monotherapy and in combination with spartalizumab. The toxicity profile of ieramilimab in combination with spartalizumab was comparable to that of spartalizumab alone. Modest antitumor activity was seen with combination treatment.Trial registration numberNCT02460224.

News (Medical) associated with Ieramilimab

14 Sep 2022

·www.biospace.com

Regeneron, Immutep Talk LAG-3 as ESMO Highlights New I-O Approaches

The March approval of Bristol Myers Squibb’s Opdualag (relatlimab and nivolumab) to treat unresectable or metastatic melanoma validated the newest checkpoint in the immuno-oncology arsenal. Since then, Regeneron, Merck, Immutep S.A. and more have been working hard to develop the next successful lymphocyte activation gene-3 (LAG-3) inhibitor. At the European Society of Medical Oncology (ESMO) Congress, Regeneron presented data from a combination of Libtayo (cemiplimab) and fianlimab, a LAG-3 inhibitor, in advanced melanoma. The Phase III study pits the combo against Merck’s Keytruda (pembrolizumab), with progression-free survival (PFS) as the primary endpoint. In two independent patient cohorts, the IO duo demonstrated greater than 60% response rates. One cohort saw a 62.5% overall response rate, six complete responses and 19 partial responses. The second had a 65% ORR with one CR and 25 PRs. Israel Lowy, M.D., Ph.D., SVP, translational and clinical sciences, oncology at Regeneron, spoke about the meaning of these data. “Combining LAG-3 and PD-1 inhibition has shown promise in advanced melanoma but achieving response rates above 50% has been challenging,” he said in a statement. A Phase III trial in first-line metastatic melanoma is currently enrolling, and Lowy said Regeneron “[looks] forward to opening additional trials with this combination in the near future.” Dr. Omid Hamid M.D., chief of research/immuno-oncology at The Angeles Clinic & Research Institute and primary investigator on the trial, referred to the consistency of the results. “With greater numbers of patients treated, we continue to see the same remarkable response rate of 63.8%,” he told BioSpace, adding that a LAG-3 dose 100x higher was still tolerable. No novel toxicities were seen and there were durable responses to therapy, he noted. In New Jersey, Merck is always looking for ways to augment the success of Keytruda. One of these is combining the blockbuster drug with favezelimab, its own anti-LAG-3 antibody. The tag-team is being studied in a Phase III trial versus standard of care in patients with previously treated metastatic PD-L1 positive colorectal cancer. And BMS is working just as hard to stay on top. The company is currently studying Opdualag in a Phase II trial for non-small cell lung cancer. Data from the NEOpredict-Lung trial were presented at ESMO. The winning melanoma combo showed early signs of efficacy in NSCLC, according to the abstract presented by principal investigator Dr. Martin Schuler of the University Hospital, Essen. Immutep is Building on LAG-3 Innovation Meanwhile, Immutep, founded by Frédéric Triebel, M.D., Ph.D., who discovered the LAG-3 immune control mechanism in 1990, is well on its way to presenting a host of data at upcoming cancer conferences. Immutep is developing eftilagimod alpha (efti) across a range of oncology and autoimmune indications, including metastatic breast cancer, NSCLC and head and neck squamous cell carcinoma (HNSCC). A combination of efti and Keytruda is being assessed in the Phase II TACTI-002 trial in first-line NSCLC. Results presented at ESMO’s s European Lung Cancer Congress 2022 showed the duo led to an ORR of 6% and a disease control rate of 36%. The ORR was even stronger at 38.6%. In an interview with BioSpace, CEO Marc Voigt said these results “doubled or tripled” those seen with Keytruda monotherapy. “This opens the door for late-stage development,” he said. Immutep expects additional data from the trial in the fourth quarter of this year. At ESMO’s Breast Cancer Congress in May, the company presented “significant data” from the Phase IIb AIPAC trial, made up of 227 patients with HER2-negative/HR-positive metastatic breast cancer. Immutep reported a statistically significant increase in innate and adaptive immune response biomarkers, monocyte and CD8 T cell counts and serum CXCL10 levels. Absolute lymphocyte count was demonstrated in the efti group, but not the placebo cohort. Voigt shared that Immutep has “the chance to move forward” to Phase III in both NSCLC and metastatic breast cancer. PD-1 inhibitors like Keytruda and Opdivo (nivolumab) have shown formidable success since the mid-2010s. LAG-3, an MHC class II ligand structurally and genetically related to CD4, is generating excitement because the inhibition of this gene can enable them to work in more patients. A Unique Mechanism of Action While BMS, Merck and Regeneron are focused on blocking LAG-3 on the T cell to keep it active, Voigt said Immutep is putting a different spin on it. “We are touching the other side of the interaction in MHC class II,” he said. “We activate the antigen-presenting cells to boost the immune system on a broader scale.” While Keytruda boosts the T cell response, “we are working on the antigen-presenting cells which are involved in generating more CD8 and CD4 T cells and more NK cells,” he explained. In this way, Voigt continued, there are “potentially more targets for anti-PD-1 to work on.” Aside from Merck, Immutep has programs partnered with Pfizer and GSK and has out-licensed an antagonist antibody targeting LAG-3, LAG525, to Novartis. Efti has also attracted the attention of the Maria Skłodowska-Curie National Research Institute in Warsaw, Poland. On Sept. 6, Immutep announced an investigator-initiated Phase II trial assessing efti in combination with Keytruda and radiotherapy in the neoadjuvant setting in up to 40 patients with select soft tissue sarcoma (STS). Immutep expects to dose the first patient in the first half of 2023 with initial interim data expected in Q4 2024. This trial will be efti’s first test in the neoadjuvant setting, Triebel told BioSpace. “The current successes of efti plus pembro (Keytruda) in the first- and second-line metastatic disease settings encourage us to ‘climb the ladder’ and test the same combo in early disease,” he said. Triebel added that “immunotherapeutic approaches should be used at the earliest possible stage of the disease” in STS. LAG-3: The Possibilities Hamid concurred, saying he sees LAG-3 combinations "moving into the adjuvant and the neoadjuvant field quickly to show response and benefit.” He also discussed the potential of the LAG-3/PD-1 combination to improve two other immunotherapy approaches: Tumor-infiltrating lymphocytes (TIL) therapy and immune-mobilizing monoclonal TCRs against cancer (ImmTAC). Hamid pointed to Immunocore’s IMC-F106C, a PRAME×CD3 ImmTAC therapy, as an example. Immunocore presented data at ESMO demonstrating doses of the drug were clinically active and showed “consistent and robust interferon gamma induction” – a specific marker of T cell activation. Durable responses were observed in two of six patients with cutaneous melanoma; two of four patients with ovarian cancer; and three of six patients with tebentafusp-naïve uveal melanoma. Hamid said LAG-3 “is the best backbone to future triplet trials in melanoma.”

AntibodyImmunotherapyCollaborate

28 Jul 2022

·www.globenewswire.com

Immutep Quarterly Activities Report

Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activityBiomarker and multivariate analysis data from the completed Phase IIb AIPAC trial reported, confirming efti is activating the immune system and helping patients live longerFour world leading oncologists join the Clinical Advisory BoardWell-funded with ~$80 million in cash, giving Immutep an expected cash runway into early CY2024 SYDNEY, AUSTRALIA, July 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (“efti”) and IMP761 for the quarter ended 30 June 2022 (Q4 FY22). Efti Development Program for Cancer AIPAC - clinical trialsNew biomarker and multivariate analysis data from the Phase IIb AIPAC trial was reported at ESMO’s Breast Cancer Congress in May 2022. The AIPAC trial evaluated efti in combination with paclitaxel chemotherapy in 227 patients with HER2-negative/HR positive metastatic breast cancer (HR+ MBC). While the final Overall Survival results from this trial were reported in November 2021, the biomarker analysis reported highly valuable additional insights. The analysis showed a statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8+ T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) was observed in the efti group, but not in the placebo group. These improved immune parameters correlated with improved overall survival of the patients, confirming efti is activating the immune system and helping patients live longer. In addition, an observed early rise in ALC in patients treated with efti may provide clinicians with a potential predictor of improved survival, helping them to determine early on if continued treatment with efti is beneficial. The exploratory analysis also identified six patient subgroups that showed improvements in Overall Survival (OS). These subgroups are therefore relevant for patient population selection for future late-stage studies in breast cancer. Regulatory interactions are ongoing for the further clinical development program for efti in MBC, including with the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). This follows feedback from the EMA regarding the efti program received in October 2021 and the FDA in March 2022. In light of the exciting 1st line NSCLC data from TACTI-002 (discussed below) Immutep is reviewing clinical plans for MBC and NSCLC in order to potentially prioritize one indication. TACTI-002 (also designated KEYNOTE-PN798) - Phase II clinical trialNew data from 1st line NSCLC patients (Part A) from TACTI-002 was reported in a prestigious Oral Presentation at the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting in June 2022. The data showed TACTI-002 met its primary objective for 1st line NSCLC patients in this PD-L1 all-comer trial. Immutep reported an Overall Response Rate of 38.6% to the combination of efti plus pembrolizumab and favourable anti-tumour activity. Encouraging responses were demonstrated in all PD-L1 status groups, including patients who were PD-L1 negative or PD-L1 low, both groups were less likely to respond to anti-PD-1 monotherapy. Immutep also reported improving secondary endpoints, Disease Control Rate (DCR) and interim median Progression Free Survival (PFS), across all PD-L1 expression levels. Efti continues to be safe and well tolerated, with a safety profile consistent with previously reported studies for pembrolizumab monotherapy. The results are supportive of continued late-stage clinical development of efti in 1st line NSCLC. New interim data from 2nd line NSCLC patients (Part B) has been selected for a poster presentation at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) taking place in August 2022 in Vienna, Austria. WCLC is the world's largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. TACTI-003 - Phase IIb clinical trial Recruitment is ongoing for 1st line head and neck squamous cell carcinoma (HNSCC) patients for Immutep’s TACTI-003 trial, with 39 patients out of approximately 154 enrolled to date across the now 24 active trial sites. TACTI-003 is a Phase IIb multicentre, open label, randomised and controlled trial. It was granted fast track designation for 1st line HNSCC by the US FDA in 2021. Immutep presented the trial design for TACTI-003 at the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting held in June. Recruitment and trial updates are expected to be reported throughout the remainder of 2022 and into 2023. INSIGHT-003 - triple combinationPatient recruitment is ongoing for the INSIGHT-003 investigator-initiated trial, with 13 out of a total of 20 patients already enrolled. INSIGHT-003 focuses on a patient population with NSCLC adenocarcinomas and evaluates a triple combination therapy consisting of efti and an existing approved standard of care combination of chemotherapy (carboplatin, pemetrexed) and an anti-PD-1 therapy. Interim results from the study are expected to be reported in Q4 2022. The trial is being conducted by the Institute of Clinical Cancer Research (IKF) at Northwest Hospital, Frankfurt, Germany. Potential new trials for efti in cancer Due to the positive data from efti presented at ASCO 2022 and other conferences, Immutep has been approached for potential new investigator-initiated trials as well as other potential collaborations for efti in various indications and combinations; we are currently assessing these opportunities. It is very encouraging to see the increased level of industry interest and willingness to support and fund further trials for efti in cancer because of the growing body of positive data generated from efti clinical trials thus far. At this stage, discussions with various parties are incomplete and still subject to negotiation. Once an agreement is reached, the Company will provide further details in a market announcement. IMP761 Development Program for Autoimmune DiseasePreclinical development steps are continuing for IMP761, prior to advancing the candidate into clinical trials. This includes development of a GMP-compliant manufacturing process for IMP761. The GMP manufacturing at 200 litre scale is ongoing. IMP761 is Immutep’s immunosuppressive agonist antibody to LAG-3 which will be tested to treat the causes of autoimmune disease, such as inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis, rather than merely treating the symptoms. Partnering Updates CYTLIMICImmutep signed clinical collaboration, service and supply agreements with the Japanese biotech, CYTLIMIC (an affiliate of NEC) in 2019 to support its development of a therapeutic cancer vaccine. CYTLIMIC has been conducting studies of CYT001, its lead cancer vaccine which comprises peptides designed using artificial intelligence from the HSP70 and GPC-3 proteins, plus two adjuvants, efti and Hiltonol. Based on a comprehensive business evaluation, CYTLIMIC has determined to dissolve the company and to transfer its own patents and licensing rights to NEC accordingly. Investigations into CYT001 will not be continuing whilst NEC assesses the future of this cancer vaccine program. EAT COVIDConducted and funded by the University Hospital Pilsen, Czech Republic, the Phase II EAT COVID study was evaluating the Company’s lead product candidate efti in hospitalised patients with COVID-19. The study aimed to boost a patient’s immune response to prevent development of severe COVID-19 symptoms that require intensive care and can lead to respiratory failure and death. While independently reviewed safety run-in data prompted the Company to initiate enrolment for the randomised portion of the study in January 2021, recruitment into the trial has been slow. Accordingly, Immutep has decided to discontinue the supply of efti for this trial and to terminate the collaboration with the University Hospital Pilsen. Immutep only incurred minimal costs for this investigator-initiated trial. Intellectual PropertyDuring the quarter, Immutep and its partner Novartis AG were granted a new patent for ieramilimab (Novartis code: LAG525), a humanised LAG-3 antagonist antibody derived from Immutep's IMP701 antibody, by the Eurasian Patent Office. The patent protects ieramilimab in the member states of the Eurasian Patent Convention, namely Armenia, Azerbaijan, Belarus, Kirgizstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan. The expiry date of the new patent is 13 March 2035. Corporate Update Clinical Advisory Board Immutep was delighted to welcome four world leading oncologists to its Clinical Advisory Board (CAB) during the quarter: Scott Antonia, M.D., Ph.D. of the Duke Cancer Institute Center for Cancer ImmunotherapyLeisha A Emens, M.D., Ph.D. Professor of Medicine at the UPMC Hillman Cancer CenterMartin Forster, M.D., Ph.D., Associate Professor at University College London (UCL)Hans Wildiers, M.D., Ph.D. of the University Hospital Leuven, Belgium The CAB serves as a strategic resource for advancing Immutep’s pipeline of LAG-3 programs, including efti, especially in NSCLC and MBC. Financial SummaryOverall, the financial performance for the quarter ended 30 June 2022 (i.e. Q4 FY22) was very pleasing. Cash receipts from customers Q4 increased to $96k, compared to $8k in the previous quarter (i.e. Q3 FY22). The net cash used in G&A activities in the quarter was $361k compared to $1.6 million in Q3 FY22. The decrease compared with the last quarter is mainly due to the inclusion of certain annual expense prepayments in the previous quarter. Payments to Related Parties for the quarter includes $189k in payment of Non-Executive Director’s fees and Executive Director’s remuneration. The net cash used in Research and Development activities in the quarter was $7.62 million, compared to $8.13 million in Q3 FY22. The lower cash outflows in Q4 FY22 were mainly due to the decrease of efti and IMP761 contract manufacturing payments. The cash outflow for clinical trial activities increased compared with Q3 FY 22 and were in line with increased activity in TACTI-003. Total net cash outflows used in operating activities in the quarter was $9.28 million compared to $10.95 million in Q3 FY22. The Company’s cash and cash equivalent balance as at 30 June 2022 was approximately $80 million compared to a balance of $87 million as at 31 March 2022. Immutep’s higher than planned cash balance continues to put the Company in a strong financial position with an expected cash reach based on current estimates of early calendar 2024. The company will continue to manage its strong cash balance carefully as it reviews its overall clinical strategy, particularly in light of the various potential opportunities for the development of efti in cancer. About ImmutepImmutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com

CollaborateAntibodyFinancial StatementFirst in ClassVaccine

28 Jul 2022

·www.biospace.com

Immutep Quarterly Activities Report - July 28, 2022

Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activity Biomarker and multivariate analysis data from the completed Phase IIb AIPAC trial reported, confirming efti is activating the immune system and helping patients live longer Four world leading oncologists join the Clinical Advisory Board Well-funded with ~$80 million in cash, giving Immutep an expected cash runway into early CY2024 SYDNEY, AUSTRALIA, July 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (“efti”) and IMP761 for the quarter ended 30 June 2022 (Q4 FY22). Efti Development Program for Cancer AIPAC - clinical trials New biomarker and multivariate analysis data from the Phase IIb AIPAC trial was reported at ESMO’s Breast Cancer Congress in May 2022. The AIPAC trial evaluated efti in combination with paclitaxel chemotherapy in 227 patients with HER2-negative/HR positive metastatic breast cancer (HR+ MBC). While the final Overall Survival results from this trial were reported in November 2021, the biomarker analysis reported highly valuable additional insights. The analysis showed a statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8+ T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) was observed in the efti group, but not in the placebo group. These improved immune parameters correlated with improved overall survival of the patients, confirming efti is activating the immune system and helping patients live longer. In addition, an observed early rise in ALC in patients treated with efti may provide clinicians with a potential predictor of improved survival, helping them to determine early on if continued treatment with efti is beneficial. The exploratory analysis also identified six patient subgroups that showed improvements in Overall Survival (OS). These subgroups are therefore relevant for patient population selection for future late-stage studies in breast cancer. Regulatory interactions are ongoing for the further clinical development program for efti in MBC, including with the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). This follows feedback from the EMA regarding the efti program received in October 2021 and the FDA in March 2022. In light of the exciting 1st line NSCLC data from TACTI-002 (discussed below) Immutep is reviewing clinical plans for MBC and NSCLC in order to potentially prioritize one indication. TACTI-002 (also designated KEYNOTE-PN798) - Phase II clinical trial New data from 1st line NSCLC patients (Part A) from TACTI-002 was reported in a prestigious Oral Presentation at the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting in June 2022. The data showed TACTI-002 met its primary objective for 1st line NSCLC patients in this PD-L1 all-comer trial. Immutep reported an Overall Response Rate of 38.6% to the combination of efti plus pembrolizumab and favourable anti-tumour activity. Encouraging responses were demonstrated in all PD-L1 status groups, including patients who were PD-L1 negative or PD-L1 low, both groups were less likely to respond to anti-PD-1 monotherapy. Immutep also reported improving secondary endpoints, Disease Control Rate (DCR) and interim median Progression Free Survival (PFS), across all PD-L1 expression levels. Efti continues to be safe and well tolerated, with a safety pro with previously reported studies for pembrolizumab monotherapy. The results are supportive of continued late-stage clinical development of efti in 1st line NSCLC. New interim data from 2nd line NSCLC patients (Part B) has been selected for a poster presentation at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) taking place in August 2022 in Vienna, Austria. WCLC is the world's largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. TACTI-003 - Phase IIb clinical trial Recruitment is ongoing for 1st line head and neck squamous cell carcinoma (HNSCC) patients for Immutep’s TACTI-003 trial, with 39 patients out of approximately 154 enrolled to date across the now 24 active trial sites. TACTI-003 is a Phase IIb multicentre, open label, randomised and controlled trial. It was granted fast track designation for 1st line HNSCC by the US FDA in 2021. Immutep presented the trial design for TACTI-003 at the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting held in June. Recruitment and trial updates are expected to be reported throughout the remainder of 2022 and into 2023. INSIGHT-003 - triple combination Patient recruitment is ongoing for the INSIGHT-003 investigator-initiated trial, with 13 out of a total of 20 patients already enrolled. INSIGHT-003 focuses on a patient population with NSCLC adenocarcinomas and evaluates a triple combination therapy consisting of efti and an existing approved standard of care combination of chemotherapy (carboplatin, pemetrexed) and an anti-PD-1 therapy. Interim results from the study are expected to be reported in Q4 2022. The trial is being conducted by the Institute of Clinical Cancer Research (IKF) at Northwest Hospital, Frankfurt, Germany. Potential new trials for efti in cancer Due to the positive data from efti presented at ASCO 2022 and other conferences, Immutep has been approached for potential new investigator-initiated trials as well as other potential collaborations for efti in various indications and combinations; we are currently assessing these opportunities. It is very encouraging to see the increased level of industry interest and willingness to support and fund further trials for efti in cancer because of the growing body of positive data generated from efti clinical trials thus far. At this stage, discussions with various parties are incomplete and still subject to negotiation. Once an agreement is reached, the Company will provide further details in a market announcement. IMP761 Development Program for Autoimmune Disease Preclinical development steps are continuing for IMP761, prior to advancing the candidate into clinical trials. This includes development of a GMP-compliant manufacturing process for IMP761. The GMP manufacturing at 200 litre scale is ongoing. IMP761 is Immutep’s immunosuppressive agonist antibody to LAG-3 which will be tested to treat the causes of autoimmune disease, such as inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis, rather than merely treating the symptoms. Partnering Updates CYTLIMIC Immutep signed clinical collaboration, service and supply agreements with the Japanese biotech, CYTLIMIC (an affiliate of NEC) in 2019 to support its development of a therapeutic cancer vaccine. CYTLIMIC has been conducting studies of CYT001, its lead cancer vaccine which comprises peptides designed using artificial intelligence from the HSP70 and GPC-3 proteins, plus two adjuvants, efti and Hiltonol. Based on a comprehensive business evaluation, CYTLIMIC has determined to dissolve the company and to transfer its own patents and licensing rights to NEC accordingly. Investigations into CYT001 will not be continuing whilst NEC assesses the future of this cancer vaccine program. EAT COVID Conducted and funded by the University Hospital Pilsen, Czech Republic, the Phase II EAT COVID study was evaluating the Company’s lead product candidate efti in hospitalised patients with COVID-19. The study aimed to boost a patient’s immune response to prevent development of severe COVID-19 symptoms that require intensive care and can lead to respiratory failure and death. While independently reviewed safety run-in data prompted the Company to initiate enrolment for the randomised portion of the study in January 2021, recruitment into the trial has been slow. Accordingly, Immutep has decided to discontinue the supply of efti for this trial and to terminate the collaboration with the University Hospital Pilsen. Immutep only incurred minimal costs for this investigator-initiated trial. Intellectual Property During the quarter, Immutep and its partner Novartis AG were granted a new patent for ieramilimab (Novartis code: LAG525), a humanised LAG-3 antagonist antibody derived from Immutep's IMP701 antibody, by the Eurasian Patent Office. The patent protects ieramilimab in the member states of the Eurasian Patent Convention, namely Armenia, Azerbaijan, Belarus, Kirgizstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan. The expiry date of the new patent is 13 March 2035. Corporate Update Clinical Advisory Board Immutep was delighted to welcome four world leading oncologists to its Clinical Advisory Board (CAB) during the quarter: Scott Antonia, M.D., Ph.D. of the Duke Cancer Institute Center for Cancer Immunotherapy Leisha A Emens, M.D., Ph.D. Professor of Medicine at the UPMC Hillman Cancer Center Martin Forster, M.D., Ph.D., Associate Professor at University College London (UCL) Hans Wildiers, M.D., Ph.D. of the University Hospital Leuven, Belgium The CAB serves as a strategic resource for advancing Immutep’s pipeline of LAG-3 programs, including efti, especially in NSCLC and MBC. Financial Summary Overall, the financial performance for the quarter ended 30 June 2022 (i.e. Q4 FY22) was very pleasing. Cash receipts from customers Q4 increased to $96k, compared to $8k in the previous quarter (i.e. Q3 FY22). The net cash used in G&A activities in the quarter was $361k compared to $1.6 million in Q3 FY22. The decrease compared with the last quarter is mainly due to the inclusion of certain annual expense prepayments in the previous quarter. Payments to Related Parties for the quarter includes $189k in payment of Non-Executive Director’s fees and Executive Director’s remuneration. The net cash used in Research and Development activities in the quarter was $7.62 million, compared to $8.13 million in Q3 FY22. The lower cash outflows in Q4 FY22 were mainly due to the decrease of efti and IMP761 contract manufacturing payments. The cash outflow for clinical trial activities increased compared with Q3 FY 22 and were in line with increased activity in TACTI-003. Total net cash outflows used in operating activities in the quarter was $9.28 million compared to $10.95 million in Q3 FY22. The Company’s cash and cash equivalent balance as at 30 June 2022 was approximately $80 million compared to a balance of $87 million as at 31 March 2022. Immutep’s higher than planned cash balance continues to put the Company in a strong financial position with an expected cash reach based on current estimates of early calendar 2024. The company will continue to manage its strong cash balance carefully as it reviews its overall clinical strategy, particularly in light of the various potential opportunities for the development of efti in cancer. About Immutep Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website or by contacting: Australian Investors/Media: Catherine Strong, Citadel-MAGNUS +61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media: Tim McCarthy, LifeSci Advisors +1 (212) 915.2564; tim@lifesciadvisors.com

CollaborateAntibodyFinancial StatementFirst in ClassVaccine

100 Deals associated with Ieramilimab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Ieramilimab	-	DB16419

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 2	AU	Novartis Pharmaceuticals Corp.	17 Jun 2015
Advanced Malignant Solid Neoplasm	Phase 2	TW	Novartis Pharmaceuticals Corp.	17 Jun 2015
Advanced Malignant Solid Neoplasm	Phase 2	IT	Novartis Pharmaceuticals Corp.	17 Jun 2015
Advanced Malignant Solid Neoplasm	Phase 2	BE	Novartis Pharmaceuticals Corp.	17 Jun 2015
Advanced Malignant Solid Neoplasm	Phase 2	JP	Novartis Pharmaceuticals Corp.	17 Jun 2015
Advanced Malignant Solid Neoplasm	Phase 2	HK	Novartis Pharmaceuticals Corp.	17 Jun 2015
Advanced Malignant Solid Neoplasm	Phase 2	US	Novartis Pharmaceuticals Corp.	17 Jun 2015
Advanced Malignant Solid Neoplasm	Phase 2	CA	Novartis Pharmaceuticals Corp.	17 Jun 2015
Hematologic Neoplasms	Phase 2	US	Novartis Pharmaceuticals Corp.	-
Melanoma	Phase 2	US	Novartis Pharmaceuticals Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03499899 (CTgov)	Phase 2	Triple Negative Breast Cancer \| Advanced Triple-Negative Breast Carcinoma	88	PDR001+LAG525 (LAG525 + PDR001)	hbipmhidvn(rhybkwsplf) = frfjhjmkaz jaivsorvfn (qriurljnaf, oueicbvqpy - bfmjktisvl) View more	-	13 May 2022
				Carboplatin+LAG525 (LAG525 + Carboplatin)	hbipmhidvn(rhybkwsplf) = yvhwjdutda jaivsorvfn (qriurljnaf, nepcknhctr - rwjmwzqaue) View more
NCT02460224 (Pubmed \| J Immunother Cancer)	Phase 1/2	Advanced cancer	255	Ieramilimab+Spartalizumab	hycgrmxkdk(ltydqocnbw) = Modest antitumor activity was seen with combination treatment kvrffihabo (oydtyjqsrw ) View more	Positive	01 Feb 2022
NCT03499899 (ESMO2021) Manual	Phase 2	Triple Negative Breast Cancer First line \| Second line ER Negative \| PR Negative \| HER2 Negative	88	LAG525+Spartalizumab	(maywolndzp) = bqwxokmbwa ybsbiievxj (jesnxdxtry, 0.1 - 24.9) View more	Negative	16 Sep 2021
				LAG525+Spartalizumab+carboplatin	(maywolndzp) = mokwhawkip ybsbiievxj (jesnxdxtry, 17.4 - 50.5) View more
NCT03484923 (PLATforM, ESMO2021) Manual	Phase 2	Unresectable Melanoma	175	ieramilimab+spartalizumab	(mzfrwakfjy) = dbrhzauafn hlcxgfxfdt (ldlviisigw ) View more	Negative	16 Sep 2021
				capmatinib+spartalizumab	(mzfrwakfjy) = kraywhorhw hlcxgfxfdt (ldlviisigw ) View more
NCT03365791 (CTgov)	Phase 2	Adenocarcinoma of Esophagus \| Ovarian adenocarcinoma \| Small Cell Lung Cancer \| stomach adenocarcinoma \| Castration-Resistant Prostatic Cancer \| Neuroendocrine Tumors \| Soft Tissue Sarcoma \| Diffuse Large B-Cell Lymphoma	76	PDR001+LAG525	tnocqiablf(bnywafvoie) = xanaegsrgl bmydayeqgn (xwzkgvyddm, jctlviaime - khkzbzgqvy) View more	-	19 Apr 2021
NCT02460224 (Phase II, SITC2020)	Phase 2	Neoplasms	235	LAG525 + spartalizumab	azjtahjoiq(aimpoaljiy) = 21% ooliinuovm (rmyvlxdcws ) View more	Positive	09 Nov 2020
NCT03365791 (ASCO2019) Manual	Phase 2	HR-positive/HER2-low Solid Tumors \| Hematologic Neoplasms	76	spartalizumab+LAG525	(rubvymnqwv) = 0.17 (Pr=0.071) dlvkmoqvpm (hpyihyllrw ) View more	Positive	01 Jun 2019
NCT02460224 (ASCO2018) Manual	Phase 1/2	Advanced cancer	240	LAG525	(blcrfatokh) = pbrcsmlwwg otdyuzhhdl (ystwzrhnok ) View more	Positive	04 Jun 2018
				LAG525+spartalizumab	(iuyvgbbdoq) = jtgjmjrhrp pfxiaubwdu (nqpyprqbti ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis